Imaging and therapy in prostate cancer using prostate specific membrane antigen radioligands.
Br J Radiol
; 97(1160): 1391-1404, 2024 Aug 01.
Article
in En
| MEDLINE
| ID: mdl-38733571
ABSTRACT
Prostate specific membrane antigen (PSMA) directed PET imaging has rapidly transformed prostate cancer workup over the past decade and paved the way for a theranostic approach using 177Lu-labelled PSMA radioligand therapy (RLT). This review gives an overview of the underlying principles behind PSMA as a target; the current use of PSMA PET in prostate cancer imaging and benefits compared to conventional imaging; and therapeutic applications including optimisation of patient selection. It also explores the evidence base of PSMA PET for other indications not in routine clinical use and the future of PSMA-directed RLT.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Prostatic Neoplasms
/
Radiopharmaceuticals
/
Glutamate Carboxypeptidase II
/
Antigens, Surface
Limits:
Humans
/
Male
Language:
En
Journal:
Br J Radiol
Year:
2024
Document type:
Article
Affiliation country: